JX10 for Acute Ischemic Stroke
This study is testing a drug called JX10 against a placebo (an inactive substance) in people who have had an acute ischemic stroke (a stroke caused by a blood clot). The main goal is to see if JX10 can improve how well people recover and reduce their symptoms 90 days after their stroke. Researchers will also be carefully watching for any serious side effects, specifically bleeding in the brain, within 36 hours of treatment. You might be able to join if you are between 18 and 90 years old, have had a recent ischemic stroke, and meet other specific medical criteria. The study aims to enroll 740 participants.
- Study design
- This is an interventional study comparing JX10 to a placebo. Participants will be randomly assigned to receive either JX10 or placebo.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants' functional outcomes will be measured at 90 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
At a glance
Conditions
NCT06990867
Where you'd take part
This study runs at 83 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Corxel Investigational site
Lille, Francestudy coordinator listed
Recruiting
Corxel Investigational site
Paris, Francestudy coordinator listed
Recruiting
Corxel Investigational site
Ibaraki, Japanstudy coordinator listed
Recruiting
Corxel Investigational site
Toyota, Japanstudy coordinator listed
Recruiting
Corxel Investigational Site
Long Beach, Californiastudy coordinator listed
Recruiting
Corxel Investigational Site
Sacramento, Californiastudy coordinator listed
Recruiting
Corxel Investigational Site
Colorado Springs, Coloradostudy coordinator listed
Recruiting
Corxel Investigational Site
Washington D.C., District of Columbiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Senior Director, Clinical Operations · STUDY_DIRECTOR · Corxel Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Efficacy: Proportion of participants with no or minimal symptoms (mRS score 0-1) at 90 days90 days
- Safety: Incidence of symptomatic intracranial hemorrhage within 36 hours post-randomizationWithin 36 hours post-randomization